Combining Thiopurine and Anti-TNF Agents Increases Lymphoma Risk in Adults, Study Finds

Combining Thiopurine and Anti-TNF Agents Increases Lymphoma Risk in Adults, Study Finds
Adult patients with inflammatory bowel disease (IBD) who receive thiopurine monotherapy or anti–tumor necrosis factor (TNF) monotherapy have a higher risk of developing lymphoma when compared to untreated patients, a cohort study suggests. The risk was higher for patients treated with a combined therapy of thiopurines and anti-TNF agents than either treatment alone. The study, “Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease,” appeared in the journal JAMA. Previous studies suggested that IBD patients who receive thiopurines — drugs that inhibit the response of the immune system, known as immunosuppressants — alone or combined with anti-TNF agents may have higher risks for developing lymphoma. The two most common thiopurines used in the management of IBD for more than 30 years are azathioprine (AZA) and 6-mercaptopurine (6-MP). Data supporting the link between the use of thiopurines and anti-TNF agents and lymphoma, however, are still scarce. Now, researchers identified a group of individuals with IBD from the French National Health Insurance databases. Researchers followed a total of 189,289 IBD patients with a median age of 43, for almost seven years. Participants were classified according to their exposure to thiopurines and anti-TNF agents, resulting in four groups: those exposed to thiopurine (50,405 patients) or anti-TNF agents alone (30,294 patients); those exposed to both therapies (14, 229 patients); and those unexposed (123,069). Researchers registered an overall number
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *